Sprouty is a general inhibitor of receptor tyrosine kinase signaling

被引:0
|
作者
Reich, A [1 ]
Sapir, A [1 ]
Shilo, BZ [1 ]
机构
[1] Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel
来源
DEVELOPMENT | 1999年 / 126卷 / 18期
关键词
sprouty; EGFR; breathless; receptor tyrosine kinase; MAP kinase; Drosophila melanogaster; oogenesis;
D O I
暂无
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Sprouty was originally identified as an inhibitor of Drosophila FGF receptor signaling during tracheal development. By following the capacity of ectopic Sprouty to abolish the pattern of activated MAP kinase in embryos, we show that Sprouty can inhibit other receptor tyrosine kinase (RTK) signaling pathways, namely the Heartless FGF receptor and the EGF receptor. Similarly, in wing imaginal discs, ectopic Sprouty abolishes activated MAP kinase induced by the EGF receptor pathway. Sprouty expression is induced by the EGFR pathway in some, but not all, tissues in which EGFR is activated, most notably in follicle cells of the ovary, the wing imaginal disc and the eye disc, In the ovary, induction of sprouty expression follows the pattern of EGFR activation in the follicle cells. Generation of homozygous sprouty mutant follicle-cell clones demonstrates an essential role for Sprouty in restricting EGFR activation throughout oogenesis, At the stage when dorso-ventral polarity of the follicle cells is established, Sprouty limits the ventral expansion of the activating Gurken signal. Later, when dorsal appendage fates are determined, reduction of signaling by Sprouty facilitates the induction of inter-appendage cell fates. The capacity of Sprouty to reduce or eliminate accumulation of activated MAP kinase indicates that in vivo it intersects with the pathway upstream to MAP kinase, The ability of ectopic Sprouty to rescue lethality caused by activated Raf suggests that it may impinge upon the pathway by interacting with Raf or downstream to it.
引用
收藏
页码:4139 / 4147
页数:9
相关论文
共 50 条
  • [41] Sprouty1 regulates cardiac homeostasis by negatively regulating the receptor tyrosine kinase pathways in heart
    Jaffre, F.
    Bussen, M.
    Flohrschutz, I.
    Martin, G. R.
    Engelhardt, S.
    CARDIOVASCULAR RESEARCH, 2012, 93 : S95 - S96
  • [42] CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma
    Odintsov, Igor
    Ortiz, Michael, V
    Khodos, Inna
    Mattar, Marissa S.
    Lui, Allan J. W.
    Kohsaka, Shinji
    de Stanchina, Elisa
    Bender, Julia L. Glade
    Ladanyi, Marc
    Somwar, Romel
    CANCER RESEARCH, 2022, 82 (06) : 1110 - 1127
  • [43] Genome-wide Association Study Links Receptor Tyrosine Kinase Inhibitor Sprouty2 to Thrombocytopenia After Coronary Artery Bypass Surgery
    Karhausen, Joern
    Smeltz, Alan M.
    Qi, Wenjing
    Li, Yi-Ju
    Shah, Svati H.
    Kraus, Wiliam E.
    Mathew, Joseph P.
    Podgoreanu, Mihai V.
    Kertai, Miklos D.
    CIRCULATION, 2017, 136
  • [44] ALECTINIB HYDROCHLORIDE ALK Receptor Tyrosine Kinase Inhibitor Oncolytic
    Cole, P.
    DRUGS OF THE FUTURE, 2013, 38 (12) : 799 - 805
  • [45] Specific inhibitor of the epidermal growth factor receptor tyrosine kinase
    Fry, D.W.
    Kraker, A.J.
    McMichael, A.
    Ambroso, L.A.
    Nelson, J.M.
    Leopold, W.R.
    Connors, R.W.
    Bridges, A.J.
    Science, 1994, 265 (5175)
  • [46] Novel inhibitor for fibroblast growth factor receptor tyrosine kinase
    Kammasuda, Naparat
    Boonyarat, Chantana
    Tsunoda, Satoshi
    Sakurai, Hiroaki
    Saiki, Ikuo
    Grierson, David S.
    Vajragupta, Opa
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (17) : 4812 - 4818
  • [47] Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy
    Sloan, Barry
    Scheinfeld, Noah S.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (12) : 1324 - 1335
  • [48] Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase.
    Mathews, ST
    Srinivas, PR
    Leon, MA
    Grunberger, G
    FASEB JOURNAL, 1996, 10 (06): : 1434 - 1434
  • [49] Iressa™.: Oncolytic, EGF receptor tyrosine kinase inhibitor.
    Levin, M
    D'Souza, N
    Castañer, J
    DRUGS OF THE FUTURE, 2002, 27 (04) : 339 - 345
  • [50] Metastatic adamantinoma responds to treatment with receptor tyrosine kinase inhibitor
    Dudek, Arkadiusz Z.
    Murthaiah, Pradeep K.
    Franklin, Michael
    Truskinovsky, Alexander M.
    ACTA ONCOLOGICA, 2010, 49 (01) : 101 - 104